IRLAB Therapeutics AB (publ)

Stockholm Stock Exchange IRLAB-A.ST

IRLAB Therapeutics AB (publ) Revenue for the year ending December 31, 2023: USD 560.42 K

IRLAB Therapeutics AB (publ) Revenue is USD 560.42 K for the year ending December 31, 2023, a -90.40% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

IRLAB Therapeutics AB (publ) Revenue for the year ending December 31, 2022 was USD 5.84 M, a -74.48% change year over year.
IRLAB Therapeutics AB (publ) Revenue for the year ending December 31, 2021 was USD 22.88 M, a 62,817.49% change year over year.
IRLAB Therapeutics AB (publ) Revenue for the year ending December 31, 2020 was USD 36.36 K, a 1,214.34% change year over year.
IRLAB Therapeutics AB (publ) Revenue for the year ending December 31, 2019 was USD 2.77 K, a 36.61% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Stockholm Stock Exchange: IRLAB-A.ST

IRLAB Therapeutics AB (publ)

CEO	Dr. Kristina Torfgard Ph.D.
IPO Date	Feb. 28, 2017
Location	Sweden
Headquarters	Arvid Wallgrens Backe 20
Employees	32
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials Research & Consulting

Description

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.

Key trends

Past 5 years